酒石酸锑钾水合物
酒石酸锑钾水合物结构式
|
常用名 | 酒石酸锑钾水合物 | 英文名 | potassium antimony tartrate hydrate |
|---|---|---|---|---|
| CAS号 | 331753-56-1 | 分子量 | 475.01500 | |
| 密度 | 2.607 | 沸点 | N/A | |
| 分子式 | C8H10KO13Sb | 熔点 | N/A | |
| MSDS | 中文版 美版 | 闪点 | N/A | |
| 符号 |
GHS06, GHS09 |
信号词 | Danger |
|
Novel oral phosphate binder with nanocrystalline maghemite-phosphate binding capacity and pH effect.
Int. J. Pharm. 482(1-2) , 21-6, (2015) Hyperphosphatemia is one of the main risk factors contributing to morbidity and mortality in patients with end stage renal disease. The demand for a new phosphate binder is continuously increasing since the number of patients suffering under hyperphosphatemia... |
|
|
In vitro sensitivity testing of Leishmania clinical field isolates: preconditioning of promastigotes enhances infectivity for macrophage host cells.
Antimicrob. Agents Chemother. 53 , 5197-203, (2009) Diagnostic material from patients with leishmaniasis is generally available as promastigotes, and proper testing for susceptibility to first-line drugs by the intracellular amastigote assay is frequently hampered by the poor infectivity of the promastigotes f... |
期刊文献综述：
更多...